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Abstract
Widespread use of microarrays has generated large amounts of data, the interrogation of the public microarray repositories,
identifying similarities between microarray experiments is now one of the major challenges. Approaches using defined
group of genes, such as pathways and cellular networks (pathway analysis), have been proposed to improve the
interpretation of microarray experiments. We propose a novel method to compare microarray experiments at the pathway
level, this method consists of two steps: first, generate pathway signatures, a set of descriptors recapitulating the
biologically meaningful pathways related to some clinical/biological variable of interest, second, use these signatures to
interrogate microarray databases. We demonstrate that our approach provides more reliable results than with gene-based
approaches. While gene-based approaches tend to suffer from bias generated by the analytical procedures employed, our
pathway based method successfully groups together similar samples, independently of the experimental design. The results
presented are potentially of great interest to improve the ability to query and compare experiments in public repositories of
microarray data. As a matter of fact, this method can be used to retrieve data from public microarray databases and perform
comparisons at the pathway level.
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Introduction
Since their first inception a decade ago, microarray studies have
become widely used in the research community, thanks to their
ability to assess the expression of thousands of genes in a single
laboratory event. The belief that such wealth of genomic
information the community could not afford to lose has led to the
development of microarray standards [1,2] and databases including
two major public microarray repositories, Gene Expression
Omnibus (GEO) [3] and ArrayExpress [4], in the hope of enabling
mining and exploration of newly acquired data space.
Identifying biologically meaningful information in relatively
noisy data represents a significant tasks and so far breakthrough
have been few and far between. Comparisons made on the level of
gene lists obtained by different statistical methods or from different
datasets hardly converge [5]. As a consequence, the usefulness of
the vast amounts of data stored in public repositories is subject to
debate. At the same time, it is becoming important to use more
than a single data set when analyzing microarray data [6] and
gather hundreds or thousands of samples to develop prognostic
markers [7]. Reaching such a goal is difficult when information
obtained from different experiments do not overlap. This is mainly
because the data often has been generated with different
microarray platforms, hybridization protocols, and the authors
use different methods and different thresholds to calculate
differentially expressed genes (DEGs) [8] . Finding ways to reliably
compare different microarray data sets is therefore important to
obtain biologically sound and reproducible information from
different datasets.
In the past years collections of all the differentially expressed
genes in a given condition that exclusively characterize that
condition, have been proposed as ‘‘gene signatures’’ for a
condition [9–11]. However, the reliability and reproducibility of
such signatures has been questioned [12,13], because of the
influence of the statistical assumptions used, or errors in the
methodology.
The number of inconsistencies and discrepancies when micro-
array data sets are compared are often reduced when approaches
that take into account biologically related sets of genes, rather than
single entities, are used [14]. The first methods developed with this
approach aimed at identifying significantly under- or over-
represented terms in the Gene Ontology [15,16]. A second
approach instead focuses in identifying significantly expressed gene
sets (sometimes incorrectly referred as pathways or cellular
networks) in a given condition using different statistical measure-
ments: Z-score [17], Gene Set Enrichment Analysis [18], signed
Fisher Exact Test [19], Global test [20] and impact analysis [21].
Recently we developed a bioinformatic environment called
Eu.Gene [22] containing a repository of all the freely available
biological pathways and different statistical methods dedicated to
analyze expression datasets and assess for enrichment in biological
pathways. EuGene relies on 2 components, (i) a database of
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the art pathway resources and (ii) a module of computation
implementing an array of tailored heuristics and statistical methods.
We developed a method allowing to assess similarity of samples
in microarray databases. To this aim we used EuGene to generate
‘‘Pathway Signatures’’, recapitulating the biologically meaningful
pathways related to some clinical/biological variable of interest,
and used them in an analysis workflow to compare different
microarray experiments.
Results
Selection of the data sets
We decided to use as reference experiments two distinct data
sets: firstly, a data set of gene expression experiments on a model
organism, Saccharomyces cerevisiae (S. cerevisiae) using the dataset from
the Rosetta compendium of deletion mutants [23], and secondly
106 experiments (grouped in 7 sets) focused on the exposure of
Homo sapiens dendritic cells (DCs) to different stimuli.
Following up the data set collection, data were pre-processed
and subject to pathway analysis (see Methods). Then, we
formulated two predictions basing on biological evidence against
which the method would be tested. With regards to the yeast
deletion mutants, we predicted that the ssn6 and tup1 mutants
would be similar, as acting as part of the same protein complex.
Regarding the dendritic cells data set, we performed a wet lab
experiments stimulating DCs with cells of the yeast S. cerevisiae in
exponential growth phase (analyzed in the same manner as the
public data) and we predicted that this experiment would show
similarity with the samples from GEO data set GSE6965 (gene
expression profile of monocyte-derived DCs stimulated for 6 h
with germinating germ tubes of Aspergillus fumigatus).
Statistical methods
We initially compared different statistical approaches for
pathway signature generation. To address the issue of the most
appropriate statistic, we evaluated both Fisher’s Exact Test (FET)
and Gene Set Enrichment Analysis (GSEA), two well-established
methods for pathway analysis. As GSEA required samples to be
divided into two distinct classes, it was not performed on the yeast
data. On the other hand both GSEA and FET were used with the
DC samples. FET produced results in the form of signed p-values,
while GSEA produced signed enrichment scores (ES).
Yeast data was in the form of log10 ratios and thus, after a
conversion to log2, was used directly for the Fisher’s Exact Test.
In order to use dendritic cell data for the Fisher’s Exact Test, we
converted the Affymetrix absolute expression values into ratios (see
Methods). When dealing with Affymetrix data, we had the choice
of cross-normalizing all the data sets, or to perform normalization
independently for each of them. Initially we compared the two
approaches. We calculated the ratios from either the comparison
between the treated samples against a common baseline (median
expression of all control experiments) or by doing paired ratios
between each treated sample and its corresponding control.
Between those two approaches, the paired ratios performed better
(data not shown) and was therefore used in all subsequent analyses
both to prevent a ‘‘smoothing’’ effect of the differences between
the data sets themselves, and to make sure that we could add more
samples without having to normalize the data sets again.
In order to selecting the most representative FET threshold,
FET thresholds were selected from the 2s interval of the binomial
distribution of the expression values.
When using FET, we addressed the question of how to use the
collection of p-values for a defined set of pathways to generate a
pathway signature with the aim of comparing different microarray
experiments. Firstly, we corrected the p-values for multiple testing
(see Methods) then our first attempt was to transform the p-values
into a measure whose magnitude would express the degree of
significance, and to that purpose, we transformed p-values into
Pathway Enrichment Factors (PEFs). Secondly, we transformed p-
values in signed binary enrichment factors (sBEFs) (see Methods):
these factors categorized p-values into three classes (significantly
up-regulated, significantly down-regulated, and not significant).
On the other hand, GSEA enrichment scores (ES) were used
directly, without any modification.
We then evaluated the performance of these metrics (sBEF or
enrichment score), as expressed in the ability of assessing similarity
according to the expectation that biologically similar experiments
should show identical or similar pathway profiles (defined as
collections of PEFs, sBEFs or enrichment scores for the pathways
used for testing).
Selection of methods to compare sets of p-values and/or
enrichment scores
To find reliable ways to group samples together, we investigated
a number of unsupervised hierarchical clustering techniques that
would be used to group together the metrics we had selected. For
this purpose, Unweighted Pair Group Method with Arithmetic
mean (UPGMA) clustering, standard hierarchical clustering, and
hierarchical clustering with support trees were used (Figures S1,
S2, S3, S4, S5). In the last case we bootstrapped samples and
pathways over 100 and 1000 iterations. Pathways and samples
were clustered with different metrics: in particular, Euclidean
distance, Pearson’s correlation and Manhattan distance were used.
We ranked the clustering methods based on the ability to group
biologically similar samples together. We found hierarchical
clustering with support trees to be the most reliable method, and
that 100 iterations were sufficient to obtain reproducible results.
Although all the distance metrics performed equally in grouping
biologically similar samples, we found Euclidean distance to give
the best visualization of the data.
Additionally, as sBEFs were categorical values, we also
evaluated the similarity between samples by using a metric suited
for this type of data (the Jaccard index).
Validation of the method
With regards to yeast data, the clustering of PEFs gave results
that were agreeing with our prediction, as the ssn6 and tup1
deletion mutants clustered together when using Pearson’s
correlation as clustering metric (Figure 1). The same results were
observed when using sBEFs, with the difference that they were
independent from the clustering metric used (Figure 2; Figures S1,
S2, S3). Pathways which shared a common profile among the two
samples included up-regulated alternative glucose metabolism
related pathways (activation of penthose-phosphate pathway,
galactose metabolism and degradation, lactose metabolism) and
down-regulated glucose metabolism pathways such as transcrip-
tional activation of glucose metabolism genes. Standard hierar-
chical clustering and UPGMA clustering results were also in
agreement with the prediction (Figures S4 and S5). On the other
hand, the Jaccard index between the two samples was 0.14, a
possible indication that such a method is less powerful than
clustering to detect biologically relevant similarity.
The results obtained with the dendritic cells data also confirmed
the predictions. wet lab experiments (analyzed in the same manner
as the public data) and we predicted that this experiment would
show similarity with the samples from GEO data set GSE6965.
The Pathway Signatures of our ad-hoc sample produced
Pathway Signatures
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growth phase, clustered together with gene expression profile of
monocyte-derived DCs stimulated for 6 h with germinating germ
tubes of A. fumigatus (Figure 3; Figures S6, S7). The result was even
more striking than the yeast data, both sBEFs and PEFs produced
results that were independent from the clustering metric used.
When using PEFs, the two samples belonged to the same sub-
cluster (data not shown), while with sBEFs they belonged to the
same sub-cluster and were the most closely associated. Pathways
which shared a similar profile among the two samples included the
Toll-like receptor signaling pathway, JAK-STAT signaling, and
cytokine-cytokine receptor interaction (Figure 4). Since we expect
the two stimuli to elicit signaling from the same pathogen
associated molecular patterns (PAMPs) these results show that
pathway-level signatures identify samples with similar biological
characteristics. Standard hierarchical clustering and UPGMA
clustering results were also in agreement with our prediction
(Figures S8 and S9). The Jaccard index between our experiment
and sample GSM160356 showed a good similarity (0.75) and the
other replicate from data set GSE6965 showed even greater
similarity (0.9). These findings show that FET pathway based
metrics are a powerful tool to identify similarity between
experiments.
On the other hand, when we clustered enrichment scores from
GSEA on the dendritic cell data, results were not in agreement
with the prediction (Figure 5): our experiment clustered with the
GSE8658 data set (response to different ligands), while GSE6965
clustered with GSE7247 (an experiment on loading DCs with
different antigens). These findings indicate that FET transformed
p-values are more effective in finding similarities among different
experiments when compared to GSEA enrichment scores.
Discussion
In this work we propose a novel method to compare microarray
experiments at the pathway level, our work addressed three major
tasks: (i) defined a metric measuring the probability of a set of
pathways to be related to some clinical/biological variable of
interest and the relative importance of that set in the context of the
biological problem, (Pathway Signature) (ii) proposed a method
using these pathway signatures to assess relative similarity of the
experiments ; (iii) proved the validity of this method applying it to
two different well defined biological problems on two independent
collections of microarray experiments.
As a proof of concept we selected datasets representing well
known stimuli in well known biological systems. One of the
datasets was from S. cerevisiae, the most extensively studied model
organism, with a well characterized genome where all the genes
are represented on the array, widely used to test bioinformatics
methods. We selected the Rosetta compendium of deletion
mutants [23] as it measures the steady state response to a very
precise alteration, the deletion of a given gene, and consequently is
relatively simple to associate a phenotype to a particular pathway
profile. As second dataset we decided to use data sets from Homo
sapiens because the majority of the experiments stored in GEO and
ArrayExpress are from human samples. We chose transcriptomic
datasets from DCs as they have some clear advantages respect to
other fields. Firstly, the cell type is well-defined, which enables the
study of the alterations in gene expression following stimulation.
Secondly, there is the possibility to perform prediction and
hypothesis-driven functional genomics studies aiming at the
reconstruction of the networks of molecular interactions charac-
terizing specific DC differentiation programs.
The aim of our work was to propose a procedure to assess
similarity between microarray experiments at the pathway level
generating ‘‘Pathway signatures’’ (PS) for a set of experiments and
use these signatures to interrogate microarray databases.
The need for better methods to identify similarities in
microarray data sets arises from the fact that although the analysis
techniques have constantly improved over the past years, one of
the biggest hurdles remains the comparability among distinct data
sets produced by different researchers and laboratories, resulting in
lists of genes which do not overlap, or overlap in a very limited
fashion. A possible reason relies on the different assumptions on
the data used by different statistical methods [8]. This is a strong
limitation, because identifying biologically similar samples would
increase the power and the reproducibility of a study, especially
since in most studies the number of samples can be a limiting
factor, which could be compensated using already published
experiments.
Also, as the number of publicly available data sets increases (at
the time of writing, GEO and Array Express host a total of
221,815 and 110,356 hybridizations, respectively), it is important
to have reliable method to compare microarray data from
different sources.
The improvements observed when comparing different exper-
iments at the pathway level [14] is coherent with the assumption
that genes never act alone in a biological system, but participate in
a cascade of networks, an approach overlooked by gene-based
analyses.
The selection of the statistical method used to measure
enrichment is central to our approach.
Different metrics have been proposed to integrate the
probability of alteration of a sector of the cellular network
(pathway) and the relative importance of that pathway in the
context of the biological problem, such as the probability vector
[19], the impact factor (IF) [21]. Other methods have been devised
for the identification of regulatory modules and their regulation
program by integrating genome-wide location and expression data
[24–27]. However, to our knowledge, these methods have not
Figure 1. Clustering of yeast samples with PEFs using Pearson’s correlation. Sample tree originated from the clustering of FET Pathway
Enrichment Factors (PEFs) values with Pearson’s correlation.
doi:10.1371/journal.pone.0004128.g001
Pathway Signatures
PLoS ONE | www.plosone.org 3 January 2009 | Volume 4 | Issue 1 | e4128Figure 2. Clustering of signed Binary Enrichment Factors (sBEFs) obtained from the FET analysis on yeast samples. Colored spots
indicate significant (p#0.05) up- (red) or down- (green) regulation. The colors of the dendrogram indicate the percentages of the tree support
(significance), from 50% (pink) to 100% (black). The inset shows the clustering of yeast mutants ssn6 and tup1. The full figure is available as Figure S1.
doi:10.1371/journal.pone.0004128.g002
Pathway Signatures
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assembled from different microarray data sets.
FETp-values had to be transformed to improve interpretation:p-
values express a probability, and the smaller they are, the more
significant the result is, while from a conceptual point of view it is
better to express pathway enrichment as a number that it is either
categorical or the more significant the greater it is. That is the
reason we first used the logarithm of reciprocal of the p-value (the
Pathway Enrichment Factor), to express the measure in a scale that
would avoid interpretation problems, the PEF was finally obtained
multiplying the value for a sign representing the ‘‘direction’’ of a
pathway, with the same approach described in [19]. Our results
showed that clustering PEFs grouped samples according to their
biological similarity. In yeast we observed as part of the same cluster
transcriptional profiles ofthe deletionmutants of, ssn6 and tup, genes
that form a co repressor complex which is responsible for repressing
a large number of S. cerevisiae genes, including glucose-responsive
genes, DNA damage genes and oxygen utilization genes [28,29]. As
ssn6 and tup1 act together, deletion of one or the other gene is
expected to yield a similar behavior. On the yeast dataset the exact
topology of the cluster was dependent on the metric used. This is
quite understandable: sets of PEFs can be noisy, as there are all the
possible ranges of p-values, and identifying which pathways were
‘‘significant’’ and which ‘‘not significant’’ was not always straight-
forward. This can influence the clustering, and so certain metrics
prove to be more useful than others, for example Pearson’s
correlation was the metric which most correctly grouped ssn6 and
tup1 in our yeast data. This result could be biologically relevant, as
although ssn6 and tup1 are part of a complex, tup1 has also a
function alone, and as a matter of fact, the pattern of significantly
altered pathway (shown by their sBEFs) in the two deletion mutants
exhibits differences. This biological difference could result in
changes in the direction in which some pathways are affected by
one deletion or by the other. Alternatively this result could reflect
greater sensitivity to technical ‘‘noise’’ in the data of some of the
metrics used.
Biclustering of PEFs on the dendritic cell data sets gave
concordant and biologically relevant results, the responses elicited
by stimulation with S. cerevisiae follow the same downstream
signalling as the ones in response to the fungus A. fumigatus [30–33]
their PEFs clustered one next to the other with all the metrics used.
On the other hand, sBEFs produced consistent results from a
clustering point of view, both for the yeast and the DCs datasets,
independently from the clustering method, thus making very easy
the identification of similar datasets.
We selected sBEFs to produce the PS as they can be easily used
as a ‘‘barcode’’ that can uniquely attached that sample, facilitating
‘‘querying’’ a database of PSs.
The observation that sBEFs, PEFs and PSs, identify similarity
between samples that are biologically meaningful, indicates that
the categorical transformation of the p-values does not affect the
observed result, concluding that the observed similarity has a
biological meaning rather than resulting from a manipulation of
the data.
When testing different methods to compare experiments at the
pathway level, we initially chose clustering because of its flexibility
and robustness in representing biological data. The type of
clustering used was biclustering with support trees over 100 or
1000 iterations [34] as implemented in TMeV [35], because the
clustering results obtained with this method are more statistically
sound as they do not depend on the original order of the genes and
the pathways. Also, clustering has been applied successfully to gene
expression studies [36–39]. From an ontological point of view the
sBEFs can be considered as categorical phenotypes, thus clustering
is a legitimate approach to classify ‘‘omics’’ data, as it has been
used on datasets of both continuous and categorical data, such as
human haplotypes in population studies [40,41] and phenotypic
observations, such as lord Fisher’s Iris data set [42], probably one
of the most widely used data sets used in clustering and pattern
recognition studies.
Yet since sBEFs are categorical rather than continuous, we
investigated the use of an alternative metric (the Jaccard index),
Figure 3. Sample clustering of Fisher’s Exact Test samples on dendritic cell data. Sample tree originated from the clustering of FET signed
Binary Enrichment Factors (sBEFs) values with Euclidean distance.
doi:10.1371/journal.pone.0004128.g003
Pathway Signatures
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data. Our results showed an excellent agreement with the
clustering for DC data, but some inconsistencies with the yeast
data, in agreement with the clustering of the PEFs for this dataset.
This could reflect some biological instances, or alternatively could
be related to noise deriving from technological issues, as the yeast
dataset is a none year old two color array. Another possibility is
that measures like the Jaccard index may not be the most robust to
capture the inherent complexity of ‘‘omics’’ data. In any case, our
future work will be aimed at improving the grouping metrics for
sBEFs.
Results with GSEA on the dendritic cell data did not satisfy our
prediction, due to the different numbers of experiments present in
the different classes and the difficulty to classify one data set in a
class or another. In fact, the grouping observed with FET scores
on DC data was absent when using GSEA data. There are two
possible reasons to this inconsistency. First of all, GSEA compares
two groups (treated versus untreated) as opposed to single-sample
analysis performed with FET. Thus, the effect of inter-donor
variability (all data sets have at least two biological replicates for
each sample) is noticeable and is not corrected by the pathway
approach. The second reason is the heterogeneity of the samples
themselves, that are subject to different treatments. As a result,
GSEA rounds everything to the lowest common denominator,
presenting an ‘‘average’’ profile where individual differences are
smoothed out. Also, the number of control and treated samples in
each data set is different (this is usually the norm when comparing
different data sets), so there is an imbalance among the various
GSEA analyses.
We can conclude that the ability to investigate at the single
sample makes the Fisher’s Exact Test conceptually more
appropriate to search for similarities among experiments in a
microarray databases, that contain a number of hybridizations
that should be interrogated without necessarily specifying the
membership to a data set or another. Lastly, GSEA requires
dividing the samples in two distinct phenotypic classes in order to
operate, and division in classes is not necessarily straightforward.
As a matter of fact, such a type of analysis is not suitable for two-
color microarrays (which present data as a ratio between treatment
and control), and therefore we were not able to use it with our
yeast data set.
Overall our results show that using pathway signatures in
conjunction with hierarchical clustering with support trees is a
powerful and useful technique to compare experiments produced
by different people and laboratories with greater power than with
the traditional analysis techniques. The results are also easier to
Figure 4. Clustering of signed Binary Enrichment Factors (sBEFs) obtained from the FET analysis on dendritic cell samples. Colored
spots indicate significant (p#0.05) up- (red) or down- (green) regulation. The colors of the dendrogram indicate the percentages of the tree support
(significance), from 50% (pink) to 100% (black). The inset shows the clustering of sample GSM160356 from data set GSE6965 with the in-house
dendritic cell experiment.
doi:10.1371/journal.pone.0004128.g004
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making this approach an ideal candidate to analyze data from
different sources. PS generated using sBEFs can be useful as
‘‘barcodes’’ to classify experiments in microarray databases and
clustering of sBEFs can be a useful way to query experiments in
databases according to their similarity at a pathway level. Thus, we
propose to store PSs as an additional experimental annotation in
the microarray databases and implement methods using pathway
signatures to query experiments in public databases and
concurrent analyses of subsets of experiments.
Despite the effectiveness of the method, there are still some
drawbacks that will need to be addressed in the future. First of all,
Fisher’s Exact Test result depend on the lower and upper cut-offs
for expression, and at the current time they are defined by the
user. We were well aware of the limitations of this method but also
aware of its robustness if the appropriate threshold is used, in
agreement with the findings from Bussemaker and Boorsma, that
proved that the Fisher’s Exact Test outperforms other metrics
when appropriately selecting the threshold [43]. Thus, we
calculated the appropriate cut-offs automatically, basing on the
2s interval of the binomial distribution of the expression values
[44], and we will implement this method directly in a future
version of Eu.Gene. Secondly, both FET and GSEA make the
assumption that genes in a pathway are independent from each
other, which is clearly not the case in real biological system. An
alternative system with the potential to dramatically improve the
results of pathway analysis has been recently proposed [21], which
keeps track of the interdependence of genes. However, its use is
Figure 5. Clustering of Enchriment scores obtained from GSEA run on the dendritic cells data sets. Red indicates up-regulation, while
green signifies down-regulation. The colors of the dendrogram indicate the percentages of the tree support (significance), from 50% (pink) to 100%
(black).
doi:10.1371/journal.pone.0004128.g005
Pathway Signatures
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requires an accurate description of causality among the events,
which is not the case for the vast majority of the pathways present
in public resources. We have partially incorporated this idea of
direction by calculating signs attached to the p-values. We plan to
increase the sophistication of the method, implementing proper
directionality of the events using curated pathway sets with a
consensus on the number, type and order of the connections
between the members of the pathway. With the ability to include
directionality, the application of methods for module network
analysis using improved PSs instead of genes [45] holds the
promise to unravel the hierarchical structure in the control of the
cellular pathways and reconstruct the modular structure deter-
mining changes in a transcriptional profile.
Methods
Data sets
Yeast data sets. A selection of 37 experiments on yeast
deletion mutants were obtained from the Rosetta compendium
[23] . Prior to analysis, data (in the form of log10 ratios) were
transformed into log2 ratios.
Dendritic cell data sets. 106 microarray samples,
corresponding to 6 data sets, were retrieved from the Gene
Expression Omnibus (GEO) database (Table 1). During the data
selection process, only samples hybridized on Affymetrix
GeneChip HG-U133 Plus 2.0 were selected. Experimental and
sample data were then downloaded using a script written in R
(http://www.r-project.org) which made use of the Bioconductor
package GEOquery (http://www.bioconductor.org). Raw data
(CEL files) were then downloaded and extracted using custom
Bash shell scripts on the Linux operating system.
In-house stimulated dendritic cell samples. Peripheral
blood mononucleated cells (PBMCs) were isolated from buffy coats
by density gradient centrifugation using Biocoll (Biochrom). CD14+
monocytes were isolated from PBMCs by positive selection using
MACS anti-CD14 microbeads and a Midi-MACSH magnetic cell
sorting device (Miltenyi Biotec, Bergisch- Gladbach,Germany). Cells
were cultured in RPMI 1640 medium (Gibco BRL) supplemented
with 2 mM L-glutamine (Sigma), 1% (v/v) non-essential amino acids,
100 mM sodium pyruvate, 50 U/ml of penicillin and 50 mg/ml of
streptomycin (Gibco BRL) containing 10% (v/v) FCS (Hyclone).
Differentiation of monocytes into dendritic cells was promoted by
addition of granulocyte-macrophage colony-stimulating factor (GM-
CSF 1000 U/ml, Chemicon)and recombinant IL-4 (1000 U/ml,
R&D Systems) for 5 days. 3*10
6 DCs were either not stimulated or
stimulated with yeast grown in exponential phase. Cells were
harvested after 4 hr of stimulation.
RNA extraction was done with TRIzol reagent (Invitrogen).
Sample pre-processing and biotin labeling were performed using
the Affymetrix GeneChipH cDNA Synthesis Kit and IVT Labeling
Kit (Affymetrix) according to the manufacturer’s protocols.
Microarray were then hybridized on Affymetrix GeneChipH
HG-U133A 2.0 microarrays, and scanned according to the
manufacturer’s instructions on a GeneChipH Scanner 3000
(Affymetrix).
Extraction, hybridization and scanning were performed by the
Genopolis consortium (University of Milano-Bicocca, Italy).
Microarray data have been submitted to GEO (accession number
GSE13901).
Pre-processing and normalization
CEL files were pre-processed and normalized with the Robust
Multi-array Average (RMA) [46] procedure, in order to obtain
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definition files (CDFs) to update the annotation of the GeneChips,
removing duplicate probes and mapping all probes to single
Entrez Gene IDs, as previously described by Dai et al. [47]. Each
data set was normalized separately. The computation was
performed with the RMAExpress program, version 1.0 beta 10
(http://rmaexpress.bmbolstad.com), on the Linux operating
system.
Selection of the pathway set
To identify biologically meaningful changes in our data sets, we
assembled two pathway sets, depending on the species. All
pathways were defined as gene lists (containing genes associated
with the pathway). The sets were prepared as follows:
N Saccharomyces cerevisiae data: All the pathways present
in Eu.Gene (n=852)
N Dendritic cell data: Pathways containing less than three
elements were excluded. Out of the remaining pathways, we
built a selection curated by experts from the DC-THERA
European network of excellence, where pathways were
classified by their level of immunological relevance. Out of
the 1038 human pathways available , 80 satisfying the experts’
criteria were selected to be part of the set.
Pathway analysis
Eu.Gene [22] was used to perform the analysis on the selected
pathway set. The analysis algorithms used were the Fisher’s Exact
Test (FET) [19] and Gene Set Enrichment Analysis (GSEA) [18].
Fisher’s Exact Test
Prior to analysis, the Affymetrix data was converted into log2
ratios using the following procedure. For each data set, treated and
untreated sample data were separated, and the expression level of
each gene in each treated sample was divided by the expression
level of the same gene in the corresponding paired untreated
sample, and the resulting ratio was log2 transformed, obtaining a
list of log2 ratios for each gene in each treated sample. The
transformed expression data, corresponding to 66 ratios, were then
used for Fisher’s Exact Test.
Yeast data, once converted to log2 ratios, was instead used
directly, without any other modifications.
The upper and lower cut-offs for FET were determined from
the 2s interval of the binomial distribution of expression values
[44].The algorithm was then run using the hypergeometric
distribution without approximation. Each pathway was associated
to a signed p-value and a matrix of signed p-values for all samples
was obtained for each data set. In order to provide a correction for
multiple testing, p-values were adjusted following the procedure by
Benjamini et al. [48].
Resulting p-values from the FET analysis were then trans-
formed prior to clustering (see below).
Gene Set Enrichment Analysis
For each data set, samples were divided into treated (‘‘Type-A’’)
and untreated (‘‘Type-B’’) groups and their expression measures
(in absolute scale) were used directly for the analysis. GSEA was
run on each data set separately, excluding pathways which
contained less than 12 genes or more than 400 genes, to improve
specificity and then significance of the obtained Enrichment Score
was assessed by performing 1000 random permutations on the
data. Enrichment scores from the analysis were then used for
clustering.
p-value transformation (FET)
The FET p-value tables from Eu.Gene were then transformed
in order to be used for hierarchical clustering. Two approaches
were used. Firstly, p-values were transformed into Pathway
Enrichment Factors (PEF) as follows:
+log2 1=p{value ðÞ
where the sign is determined by the Sign of the p-value obtained
from the FET analysis in Eu.Gene.
With the second approach, p-values were converted into signed
Binary Enrichment Factors (sBEFs)
+1i f p -valueƒ0:05 depending on Sign
0i f p -valuew0 or Sign is not defined

In the case of sBEFs, after transformation they were filtered to
exclude non-significant pathways in all the samples (i.e., rows
containing only zeroes in all samples).
Clustering
Hierarchical clustering was performed with the TIGR Multi-
experiment Viewer (TMeV), version 4.1.1 [35]. Specifically, we
used standard hierarchical clustering and clustering with support
trees [34]: in the latter case pathways and samples were
bootstrapped over 100 and 1000 iterations. Euclidean distance,
Pearson’s correlation and Manhattan distance were used as
distance metrics, with average linkage clustering. Both pathways
and samples were clustered.
Unweighted Pair Group Method with Arithmetic mean
(UPGMA) clustering was performed using Eu.Gene’s internal
‘‘Path-Blast’’ function, creating similarity trees between different
experiments in each data set with a p-value threshold of 0.05.
Jaccard index calculation
From the sBEF matrix, the Jaccard similarity index was
calculated for every possible pairing between the various sample
columns. The computation was performed with the Python
programming language, using the scipy-hcluster package (http://
code.google.com/p/scipy-cluster/).
Supporting Information
Figure S1 Clustering of signed Binary Enrichment Factors using
Euclidean distance using support trees on yeast data. Colored
spots indicate significant (p,=0.05) up- (red) or down- (green)
regulation. The colors of the dendrogram indicate the percentages
of the tree support (significance), from 50% (pink) to 100% (black).
Found at: doi:10.1371/journal.pone.0004128.s001 (0.94 MB
PNG)
Figure S2 Clustering of signed Binary Enrichment Factors using
Pearson’s Correlation using support trees on yeast data. Colored
spots indicate significant (p,=0.05) up- (red) or down- (green)
regulation. The colors of the dendrogram indicate the percentages
of the tree support (significance), from 50% (pink) to 100% (black).
Found at: doi:10.1371/journal.pone.0004128.s002 (0.92 MB
PNG)
Figure S3 Clustering of signed Binary Enrichment Factors using
Manhattan Distance using support trees on yeast data. Colored
spots indicate significant (p,=0.05) up- (red) or down- (green)
regulation. The colors of the dendrogram indicate the percentages
of the tree support (significance), from 50% (pink) to 100% (black).
Pathway Signatures
PLoS ONE | www.plosone.org 9 January 2009 | Volume 4 | Issue 1 | e4128Found at: doi:10.1371/journal.pone.0004128.s003 (0.94 MB
PNG)
Figure S4 Standard hierarchical clustering of signed Binary
Enrichment Factors on yeast data. Colored spots indicate
significant (p,=0.05) up- (red) or down- (green) regulation.
Found at: doi:10.1371/journal.pone.0004128.s004 (0.92 MB
PNG)
Figure S5 UPGMA clustering of Fisher’s Exact Test analysis
results on yeast data.
Found at: doi:10.1371/journal.pone.0004128.s005 (0.16 MB JPG)
Figure S6 Clustering of signed Binary Enrichment Factors using
Pearson’s Correlation using support trees on dendritic cell data.
Colored spots indicate significant (p,=0.05) up- (red) or down-
(green) regulation. The colors of the dendrogram indicate the
percentages of the tree support (significance), from 50% (pink) to
100% (black).
Found at: doi:10.1371/journal.pone.0004128.s006 (0.22 MB
PNG)
Figure S7 Clustering of signed Binary Enrichment Factors using
Manhattan Distance using support trees on dendritic cell data.
Colored spots indicate significant (p,=0.05) up- (red) or down-
(green) regulation. The colors of the dendrogram indicate the
percentages of the tree support (significance), from 50% (pink) to
100% (black).
Found at: doi:10.1371/journal.pone.0004128.s007 (0.22 MB
PNG)
Figure S8 Standard hierarchical clustering of signed Binary
Enrichment Factors on dendritic cell data. Colored spots indicate
significant (p,=0.05) up- (red) or down- (green) regulation.
Found at: doi:10.1371/journal.pone.0004128.s008 (0.20 MB
PNG)
Figure S9 UPGMA clustering of Fisher’s Exact Test analysis
results on dendritic cell data.
Found at: doi:10.1371/journal.pone.0004128.s009 (0.63 MB JPG)
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